Novartis Unveils Zero Profit COVID-19 Drugs Portfolio
Dexamethasone On List For Low-Income Countries
Executive Summary
Lutz Hegemann, chief operating officer for global health at Novartis, tells Scrip the project will continue until a vaccine or curative treatments have reached the world's poorest places, not just until they are first approved in a high income country.
You may also be interested in...
Novartis Steps Up To Plate To Produce Pfizer/BioNTech COVID-19 Vaccine
In the latest example of cross-industry collaboration in these turbulent times, Novartis is joining forces with Pfizer and BioNTech to help produce their in-demand mRNA vaccine at a facility in Switzerland.
Novartis Not Tempted To Join COVID-19 Vaccines Race
While the traditional players such as Pfizer and GSK, as well as newcomer AstraZeneca, are hot in pursuit of a COVID-19 vaccine, the Swiss major is sticking to drugs, the area where "we do have deep expertise," CEO Vas Narasimhan told journalists.
Quick Listen: Scrip’s Five Must-Know Things
Join us for a quick audio roundup of five useful things to know from Scrip's recent coverage of the global biopharmaceutical industry.